Overhyped/Fading · 6.1/10
Tirzepatide
Tirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects. Jastreboff 2022 established major body-weight reduction in adults with obesity, Frias 2021 showed superiority to semaglutide 1 mg for type 2 diabetes glycemia, and Jastreboff 2025 extended the obesity and diabetes-prevention signal to 176 weeks. The trade-off is equally real: chronic benefit usually requires chronic treatment, with randomized withdrawal data showing clinically meaningful regain after stopping. Read the full breakdown →
The prediction game
Where does Tirzepatide go in 12 months?
Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Be the first scout on record for Tirzepatide. Permanent credit on this page, plus points when your call resolves.
One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
Same as above — one verification covers all your entries here.
For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.